The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2013

Filed:

Jan. 07, 2010
Applicants:

Gopalan Balasubramanian, Chennai, IN;

Sukumar Sakamuri, San Diego, CA (US);

Gajendra Singh, Chennai, IN;

Sivanesan Dharmalingam, Seoul, KR;

Franklin Pooppady Xavier, Chennai, IN;

Shridhar Narayanan, Chennai, IN;

Jeyamurugan Mookkan, Chennai, IN;

Jeganatha Sivakumar Balasubramanian, Chennai, IN;

Agneeswari Rajalingam, Chennai, IN;

Jayanarayan Kulathingal, Chennai, IN;

Inventors:

Gopalan Balasubramanian, Chennai, IN;

Sukumar Sakamuri, San Diego, CA (US);

Gajendra Singh, Chennai, IN;

Sivanesan Dharmalingam, Seoul, KR;

Franklin Pooppady Xavier, Chennai, IN;

Shridhar Narayanan, Chennai, IN;

Jeyamurugan Mookkan, Chennai, IN;

Jeganatha Sivakumar Balasubramanian, Chennai, IN;

Agneeswari Rajalingam, Chennai, IN;

Jayanarayan Kulathingal, Chennai, IN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/541 (2006.01); A61K 31/4196 (2006.01); A61K 31/4025 (2006.01); A61K 31/46 (2006.01); A61K 31/4245 (2006.01); A61K 31/497 (2006.01); A61K 31/4439 (2006.01); A61K 31/40 (2006.01); A61K 31/454 (2006.01); C07D 413/12 (2006.01); C07D 405/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.


Find Patent Forward Citations

Loading…